DDW Editor Reece Armstrong speaks to Dr Ebrahim Delpassand, CEO of RadioMedix, about scaling access to radiopharmaceuticals and the company’s attempt to innovate in hard-to-treat cancers. RA: Could you discuss RAHA-100 and your goal of democratising access to the 212Pb isotope – why is this important?    ED: One of the central challenges in radiopharmaceutical targeted alpha therapy has been that the biology […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!